Managers / Q2 2020 · view latest →
Healthcare Value Capital, LLC
CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411
Summary
Healthcare Value Capital, LLC reported $39M in U.S.-listed holdings across 19 positions for Q2 2020.
Its largest position, Glaxosmithkline, represents 10.4% of the portfolio.
Compared with Q1 2020, the fund opened 0 new positions and exited 6.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 71.7% · $28M
- Other · 28.3% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AZNNASTRAZENECA PLC | SOLD OUT | −75.0K | 0 | −$3M | $0 |
| LABORATORY CORP AMER HLDGS | SOLD OUT | −25.0K | 0 | −$3M | $0 |
| SPXLDIREXION SHS ETF TR | SOLD OUT | −120.0K | 0 | −$3M | $0 |
| ALXNALEXION PHARMACEUTICALS INC | SOLD OUT | −30.0K | 0 | −$3M | $0 |
| PROSHARES TR | SOLD OUT | −75.0K | 0 | −$1M | $0 |
| WBAWALGREENS BOOTS ALLIANCE INC | ADDED | +25.0K | 50.0K | +$976,000 | $2M |
| MENLO THERAPEUTICS INC | ADDED | +850.0K | 1.70M | +$663,000 | $3M |
| ADAMAS PHARMACEUTICALS INC | SOLD OUT | −200.0K | 0 | −$578,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | GLAXOSMITHKLINE PLC | SPONSORED ADR | 10.41% | $4M | 100.0K |
| 2 | GILDGILEAD SCIENCES INChistory → | COM | 9.82% | $4M | 50.0K |
| 3 | PROSHARES TR | ULTRAPRO SHORT S | 7.53% | $3M | 250.0K |
| 4 | MENLO THERAPEUTICS INC | COM | 7.51% | $3M | 1.70M |
| 5 | TYME TECHNOLOGIES INC | COM | 7.39% | $3M | 2.17M |
| 6 | CAHCARDINAL HEALTH INChistory → | COM | 6.66% | $3M | 50.0K |
| 7 | ABBVABBVIE INChistory → | COM | 6.27% | $2M | 25.0K |
| 8 | WBAWALGREENS BOOTS ALLIANCE INChistory → | COM | 5.41% | $2M | 50.0K |
| 9 | JAZZJAZZ PHARMACEUTICALS PLChistory → | SHS USD | 5.35% | $2M | 19.0K |
| 10 | CLOVIS ONCOLOGY INC | COM | 4.31% | $2M | 250.0K |
| 11 | CVSCVS HEALTH CORPhistory → | COM | 4.15% | $2M | 25.0K |
| 12 | MCKMCKESSON CORPhistory → | COM | 3.92% | $2M | 10.0K |
| 13 | CORAMERISOURCEBERGEN CORPhistory → | COM | 3.86% | $2M | 15.0K |
| 14 | ANTARES PHARMA INC | COM | 3.51% | $1M | 500.0K |
| 15 | GREENLANE HLDGS INC | CL A | 2.54% | $995,000 | 250.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $51M | 25 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $50M | 23 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $45M | 22 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $30M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $30M | 18 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $39M | 19 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $59M | 26 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $34M | 16 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $55M | 22 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $53M | 19 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $26M | 10 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.